An update from MDxHealth ( (MDXH) ) is now available.
MDxHealth SA reported a significant financial turnaround for the year ending December 31, 2024, with a net profit of EUR 7,031,447 compared to a net loss of EUR 28,370,081 in 2023. This improvement was driven by increased financial income and a reversal of impairments on intercompany receivables, despite an operational loss. The company’s revenue grew by 28% to $90 million, largely due to its tissue-based tests. The financial statements, prepared on a going concern basis, indicate that MDxHealth has sufficient liquidity to continue operations for at least the next twelve months, supported by a $100 million loan agreement with OrbiMed Advisors LLC.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s strong revenue growth and positive technical momentum are offset by financial instability and valuation concerns. The optimistic outlook from the earnings call strengthens the score, yet high leverage and negative profitability weigh heavily.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
MDxHealth SA is a Belgian company specializing in molecular diagnostics for cancer. The company focuses on providing advanced genomic testing services, particularly in the field of urologic cancers, with a significant market presence in the United States.
YTD Price Performance: -23.91%
Average Trading Volume: 74,512
Technical Sentiment Signal: Buy
Current Market Cap: $85.14M
For detailed information about MDXH stock, go to TipRanks’ Stock Analysis page.